Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis
Authors:
- 23 June 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 16 (9) , 1023-1033
Abstract
Predicting omalizumab treatment response has been a challenge and significant aspect for selecting suitable severe allergic asthma patients for omalizumab use.To determine which domains of pretreat...Keywords
This publication has 59 references indexed in Scilit:
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effectsJournal of Allergy and Clinical Immunology, 2013
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthmaRespiratory Medicine, 2013
- The value of FeNO measurement in childhood asthma: uncertainties and perspectivesMultidisciplinary Respiratory Medicine, 2013
- Omalizumab Protects against Allergen- Induced Bronchoconstriction in Allergic (Immunoglobulin E-Mediated) AsthmaInternational Archives of Allergy and Immunology, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Effect Sizes Based on Means2009
- Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitisAllergy, 2008
- Add‐on omalizumab improves day‐to‐day symptoms in inadequately controlled severe persistent allergic asthmaAllergy, 2008
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004